J H Fetting

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study
    J H Fetting
    Johns Hopkins Oncology Center, Baltimore, MD 21287, USA
    J Clin Oncol 16:2382-91. 1998
  2. ncbi request reprint Phase II trial of menogaril as initial chemotherapy for metastatic breast cancer
    M J Kennedy
    Johns Hopkins Oncology Center, Baltimore, MD
    Invest New Drugs 8:289-94. 1990

Detail Information

Publications2

  1. ncbi request reprint Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study
    J H Fetting
    Johns Hopkins Oncology Center, Baltimore, MD 21287, USA
    J Clin Oncol 16:2382-91. 1998
    ..The 16-week regimen features greater doxorubicin and 5-FU dose-intensity than CAF and improved scheduling of antimetabolites with sequential methotrexate and 5-FU, as well as infusion 5-FU...
  2. ncbi request reprint Phase II trial of menogaril as initial chemotherapy for metastatic breast cancer
    M J Kennedy
    Johns Hopkins Oncology Center, Baltimore, MD
    Invest New Drugs 8:289-94. 1990
    ..Mean survival in all patients entered was 15.8 months from date of entry. Menogaril at this dose and schedule has modest activity as first line therapy for metastatic breast cancer but also has significant marrow and local toxicity...